Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.60 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29678370 | 1.00 | HRH3 (0.60) | HRH3PRMT6FAAHSMN1; SMN2ALDH1A1 | |
| SCHEMBL29809589 | 0.98 | HRH3 (0.62) | HRH3PRMT6FAAHSMN1; SMN2ALDH1A1 | |
| SCHEMBL13834236 | 0.98 | HRH3 (0.62) | HRH3PRMT6FAAHSMN1; SMN2ALDH1A1 | |
| SCHEMBL2228790 | 0.98 | HRH3 (0.62) | HRH3PRMT6FAAHSMN1; SMN2ALDH1A1 | |
| SCHEMBL27912351 | 0.97 | FAAH (0.56) | HRH3PRMT6FAAHSMN1; SMN2ALDH1A1 | |
| SCHEMBL28024099 | 0.93 | FAAH (0.63) | HRH3FAAHCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL20804353 | 0.93 | FAAH (0.63) | HRH3FAAHCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL38659199 | 0.87 | CHRM3 (0.60) | FAAHCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL639856 | 0.87 | CHRM3 (0.60) | FAAHCYP19A1CYP11B1CYP11B2 | |
| SCHEMBL26115483 | 0.87 | FAAH (0.54) | HRH3FAAHALDH1A1CYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116348458-A | Imidazolylpyrimidinylamine compounds as CDK2 inhibitors | 因赛特公司 | 2023-06-27 | — | — | CN | claimed |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | INCYTE CORPORATION | 2025-07-31 | — | — | US | disclosed |
| EP-3848375-B1 | METHODS OF PREPARING INTERMEDIATES FOR TOLL-LIKE RECEPTOR MODULATORS | GILEAD SCIENCES INC (US) | 2023-12-27 | — | — | EP | disclosed |
| CN-115043840-A | Methods for preparing TOLL-like receptor modulators | 吉利德科学公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-107074860-B | Methods for preparing TOLL-like receptor modulators | 吉利德科学公司 | 2022-07-15 | — | — | CN | disclosed |
| US-11110091-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11110091-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2021-09-07 | — | — | US | disclosed |
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | HEPO PHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| EP-3848375-A1 | METHODS OF PREPARING INTERMEDIATES FOR TOLL-LIKE RECEPTOR MODULATORS | Gilead Sciences, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3848375-A1 | METHODS OF PREPARING INTERMEDIATES FOR TOLL-LIKE RECEPTOR MODULATORS | Gilead Sciences, Inc. (US) | 2021-07-14 | — | — | EP | disclosed |
| US-8367670-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120296041-A1 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2012-11-22 | — | — | US | disclosed |
| WO-2011091346-A2 | POLYMERS FUNCTIONALIZED WITH NITRILE COMPOUNDS CONTAINING A PROTECTED AMINO GROUP | BRIDGESTONE CORPORATION (JP) | 2011-07-28 | — | — | WO | disclosed |
| WO-2010077613-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100143301-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR2, TLR6 | HRH3 1263/4885PRMT6 3752/4885FAAH 4137/4885 |
| US-11110091-B2 | Modulators of toll-like receptors | TLR3, TLR2, TLR6 | HRH3 1263/4885PRMT6 3752/4885FAAH 4137/4885 |
| US-11084818-B2 | Nitrogen-containing heterocyclic compound, preparation method, intermediate, pharmaceutical composition and use | TLR7, TLR9, TLR4 | HRH3 53/4885PRMT6 4010/4885FAAH 962/4885 |
| US-20250243183-A1 | IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS | CDK2, CDK4, CDK2AP2 | HRH3 2765/4885PRMT6 1539/4885FAAH 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.